Oxytocin

also known as Syntocinon · OXT · Pitocin · IN-OXT · Syntocinon Nasal Spray · Oxytocin: Syntocinon-Spray, Novartis · Synpitan forte · Syntocinon-Spray · +16 more

Peptide targets OXTR

Developed for: schizophrenia · autism spectrum disorder · post-traumatic stress disorder · alcohol-related disorders · chronic pain syndrome · uterine disorder · alcohol dependence · obesity disorder
+87 more
· osteoarthritis, knee · Prader-Willi syndrome · dystocia · pregnancy disorder · substance abuse · autism · cervix disorder · postmenopausal atrophic vaginitis · preterm premature rupture of the membranes · autism spectrum disorder 1 · CGF1 · cocaine dependence · frontotemporal dementia · obstructive sleep apnea syndrome · opiate dependence · schizoaffective disorder · social phobia · anxiety disorder · borderline personality disorder · depressive disorder · disruptive behavior disorder · drug dependence · neurohypophyseal diabetes insipidus · nicotine dependence · obesity, hyperphagia, and developmental delay · postpartum depression · preeclampsia · substance withdrawal syndrome · substance-related disorder · tinnitus · acquired hypothalamic obesity · adenomyosis · alcohol withdrawal · amphetamine abuse · anemia · antisocial personality disorder · anxiety · binge eating disorder · body dysmorphic disorder · cardiac rhythm disease · childhood-onset schizophrenia · COVID-19 · diabetes mellitus · disease of bone structure · dyspepsia · dysthymic disorder · eating disorder · Ehlers-Danlos syndrome, hypermobility type · female infertility · fragile X syndrome · functional gastric disease · headache disorder · hemorrhagic disease · infertility disorder · leiomyoma · major depressive disorder · migraine with aura · migraine without aura · mood disorder · myocardial infarction · neuropathy, painful · newborn respiratory distress syndrome · obsessive-compulsive disorder · paranoid personality disorder · pelvis syndrome · perinatal disease · Phelan-McDermid syndrome · placenta accreta · placenta disorder · polycystic ovary syndrome · premenstrual dysphoric disorder · psychotic disorder · sunburn · toxic or drug-related embryofetopathy · uterine corpus leiomyoma · alcohol abuse · bipolar disorder · cannabis dependence · central diabetes insipidus · heart disorder · interstitial cystitis · obstetric disorder · ovarian disorder · schizotypal personality disorder · severe pre-eclampsia · sexual disorder · skin atrophy
Investigated by: University of Electronic Science and Technology of China · Wake Forest University Health Sciences · Massachusetts General Hospital · University of California, San Francisco · Medical University of South Carolina · University of North Carolina, Chapel Hill
+270 more
· University Hospital, Bonn · KU Leuven · National Institute of Mental Health (NIMH) · National Institute of Neurological Disorders and Stroke (NINDS) · Rambam Health Care Campus · Samuel Lunenfeld Research Institute, Mount Sinai Hospital · University Hospital, Toulouse · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) · Research Foundation Flanders · San Francisco Veterans Affairs Medical Center · Shalvata Mental Health Center · United States Department of Defense · University of California, Los Angeles · University of California, San Diego · University of Florida · University of Maryland, Baltimore · Yale University · Cairo University · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Northwestern University · Norwegian University of Science and Technology · PepTonic Medical AB · Sheba Medical Center · St. Olavs Hospital · University of Chicago · VA Office of Research and Development · Assiut University · Beijing Normal University · Canadian Institutes of Health Research (CIHR) · Central Institute of Mental Health, Mannheim · Emory University · George Washington University · GlaxoSmithKline · Icahn School of Medicine at Mount Sinai · Montefiore Medical Center · National Institute of Mental Health and Neuro Sciences, India · National Institute on Alcohol Abuse and Alcoholism (NIAAA) · National Institute on Drug Abuse (NIDA) · Stanford University · Tel-Aviv Sourasky Medical Center · University Hospital, Gentofte, Copenhagen · University of British Columbia · University of Calgary · VA Greater Los Angeles Healthcare System · Ain Shams Maternity Hospital · Alexander Kolevzon · Assistance Publique - Hôpitaux de Paris · Baylor College of Medicine · Ben-Gurion University of the Negev · Bezmialem Vakif University · Charite University, Berlin, Germany · David Feifel · Evdokia Anagnostou · Florida Institute for Human and Machine Cognition · Gynuity Health Projects · Hadassah Medical Organization · Hebrew University of Jerusalem · Holland Bloorview Kids Rehabilitation Hospital · Jennifer Mitchell · Kanuni Sultan Suleyman Training and Research Hospital · Lade Addiction Treatment Center · MacDonald, Kai, M.D. · Monash University · Office of Naval Research (ONR) · Oxytone Bioscience BV · RWTH Aachen University · Shana McCormack, MD · Skane University Hospital · Soroka University Medical Center · The Branco Weiss Fellowship · The University of Texas Health Science Center, Houston · University Hospital, Basel, Switzerland · University of Alabama at Birmingham · University of Arizona · all 276 on the full record

Regulatory milestones approvals, filings & regulatory actions · 1 recorded

Milestone	Jurisdiction	Brand	Indication	Date	Sentence it was read from
Approved	US (FDA)	SYNTOCINON	—	1980-04-17	fda.gov ↗

Trials 397 · started per year

today

US approved 1980

197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 033 trials
Phase 0	NCT07140237	Sep → Dec 2025 overdue	—	University of Electronic Science and Technology of China	Recruiting	No outcome recorded
Phase 0	NCT07093060	Jun → Nov 2025 overdue	—	University of Electronic Science and Technology of China	Recruiting	No outcome recorded
Phase 0	NCT03414112	Sep 2018 → Apr 2021	anorexia nervosa	University of Minnesota	Completed	No outcome recorded
Phase 0	NCT03136263	Dec 2017 → Nov 2020	attention deficit-hyperactivity disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 0	NCT03211013	Jul 2017 → Jun 2021	post-traumatic stress disorder	Palo Alto Veterans Institute for Research	Completed	No outcome recorded
Phase 0	NCT03085654	Mar 2017 → Mar 2018	—	University of Electronic Science and Technology of China	Completed	No outcome recorded
Phase 0	NCT03144115	Oct 2016 → Jun 2018	—	University of Electronic Science and Technology of China	Completed	No outcome recorded
Phase 0	NCT02741063	May 2016 → Jun 2019	—	University of Electronic Science and Technology of China	Unknown	No outcome recorded
Phase 0	NCT02469259	Feb 2016 → Feb 2018	alcohol dependence, post-traumatic stress disorder	University of California, San Francisco	Completed	No outcome recorded
Phase 0	NCT03055546	Feb 2016 → Dec 2018	—	University of Electronic Science and Technology of China	Unknown	No outcome recorded
Phase 0	NCT02361177	Jan → Apr 2016	disruptive behavior disorder	University of Texas at Austin	Withdrawn	No outcome recorded
Phase 0	NCT03084029	Jan 2016 → Jun 2017	—	University of Electronic Science and Technology of China	Completed	No outcome recorded
Phase 0	NCT02396303	Jun → Oct 2015	—	Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh	Unknown	No outcome recorded
Phase 0	NCT02564068	May 2015 → Dec 2016	obstructive sleep apnea syndrome	George Washington University	Completed	No outcome recorded
Phase 0	NCT02443727	Apr → Dec 2015	—	Rodrigo Cardenas	Completed	No outcome recorded
Phase 0	NCT02221830	Feb 2015 → Jul 2019	preeclampsia	University of Colorado, Denver	Completed	No outcome recorded
Phase 0	NCT02393443	Jan 2015 → Jul 2016	—	University of California, Los Angeles	Completed	No outcome recorded
Phase 0	NCT02393456	Jan 2015 → Jul 2016	—	University of California, Los Angeles	Completed	No outcome recorded
Phase 0	NCT02740101	Nov 2014 → Aug 2015	—	University of Electronic Science and Technology of China	Completed	No outcome recorded
Phase 0	NCT02276677	Oct 2014 → May 2015	morbid obesity	Massachusetts General Hospital	Completed	No outcome recorded
Phase 0	NCT02228031	Oct 2014 → Aug 2016	CGF1	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 0	NCT02238379	Sep 2014 → Dec 2015	—	Yale University	Completed	No outcome recorded
Phase 0	NCT02501837	Jul 2014 → Jun 2015	—	University Hospital, Bonn	Completed	No outcome recorded
Phase 0	NCT02183948	Jun → Dec 2014	—	University of Electronic Science and Technology of China	Completed	No outcome recorded
Phase 0	NCT02091817	Nov 2013 → Dec 2016	prosopagnosia	Soroka University Medical Center	Suspended	No outcome recorded
Phase 0	NCT01680718	Oct 2012 → Sep 2013	—	University of California, Los Angeles	Completed	No outcome recorded
Phase 0	NCT02566356	Sep 2012 → Sep 2017	schizophrenia	University of California, San Francisco	Completed	No outcome recorded
Phase 0	NCT01701180	Aug 2012 → Aug 2013	—	University Hospital, Bonn	Completed	No outcome recorded
Phase 0	NCT01728909	May 2012 → Oct 2014	opiate dependence, substance abuse	University of California, San Francisco	Completed	No outcome recorded
Phase 0	NCT02567032	Oct 2010 → Aug 2019	CGF1, schizophrenia	University of California, San Francisco	Completed	No outcome recorded
Phase 0	NCT02577575	Aug 2010 → Nov 2015	schizophrenia	University of California, San Francisco	Completed	No outcome recorded
Phase 0	NCT00914953	Feb → Dec 2010	—	Claremont Graduate University	Completed	No outcome recorded
Phase 0	NCT00776360	Dec 2008 → Dec 2009	functional gastric disease	Skane University Hospital	Completed	No outcome recorded

Phase 140 trials
Phase 1	NCT06332066	May 2024	—	Shalvata Mental Health Center	Unknown	No outcome recorded
Phase 1	NCT05865288	Jun 2023 → Apr 2024	eating disorder	Shalvata Mental Health Center	Unknown	No outcome recorded
Phase 1	NCT05672667	Feb → Nov 2023	—	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 1	NCT04051619	Jan 2020 → Dec 2023	substance-related disorder	Brown University	Completed	No outcome recorded
Phase 1	NCT04292444	Dec 2019 → May 2021	—	University Hospital, Bonn	Unknown	No outcome recorded
Phase 1	NCT04137432	Sep 2019 → Sep 2020	—	University Hospital, Bonn	Unknown	No outcome recorded
Phase 1	NCT03860233	Mar 2019 → Dec 2026 expected	obstructive sleep apnea syndrome	Vivek Jain	Recruiting	No outcome recorded
Phase 1	NCT02908126	Apr 2018 → Jun 2019	—	Oxytone Bioscience BV	Terminated	No outcome recorded
Phase 1	NCT03610919	Mar → Sep 2018	—	University of Electronic Science and Technology of China	Unknown	No outcome recorded
Phase 1	NCT03255148	Jul 2017 → May 2018	—	KU Leuven	Completed	No outcome recorded
Phase 1	NCT03060031	Jun 2017 → Mar 2019	—	University of Colorado, Boulder	Completed	No outcome recorded
Phase 1	NCT02881177	Jan 2017 → Jul 2018	amphetamine abuse	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT02999100	Nov 2016 → Mar 2019	—	GlaxoSmithKline	Terminated	No outcome recorded
Phase 1	NCT04330677	Sep 2016 → Jan 2020	—	University Hospital, Bonn	Completed	No outcome recorded
Phase 1	NCT03183674	Jul 2016 → Jul 2017	autism spectrum disorder	University of Sao Paulo General Hospital	Completed	No outcome recorded
Phase 1	NCT02872467	May 2016 → Mar 2023	pregnancy disorder, substance abuse	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT02911480	Apr 2016 → Feb 2017	—	Oxytone Bioscience BV	Withdrawn	No outcome recorded Stop: Business
Phase 1	NCT02069431	Feb 2016 → May 2020	—	University of Florida	Terminated	No outcome recorded Stop: Enrollment
Phase 1	NCT02745522	Dec 2015 → Mar 2017	—	University of Electronic Science and Technology of China	Completed	No outcome recorded
Phase 1	NCT02302430	Oct 2015 → May 2018	—	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT02542813	Sep → Dec 2015	—	GlaxoSmithKline	Completed	No outcome recorded
Phase 1	NCT03265899	Jul 2015 → Nov 2016	—	University Hospital, Bonn	Completed	No outcome recorded
Phase 1	NCT02098421	Nov 2014 → Apr 2016	—	Icahn School of Medicine at Mount Sinai	Completed	No outcome recorded
Phase 1	NCT01945957	Sep 2014 → Jan 2017	autism spectrum disorder	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT02213029	Aug 2014 → Feb 2016	—	GlaxoSmithKline	Terminated	No outcome recorded
Phase 1	NCT02058251	Feb 2014 → Jan 2017	alcohol-related disorders	Medical University of South Carolina	Completed	No outcome recorded
Phase 1	NCT01983514	Oct 2013 → Feb 2014	—	OptiNose AS	Completed	No outcome recorded
Phase 1	NCT01929161	Sep 2013 → Sep 2014	—	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT01912378	Aug 2013 → May 2015	autism spectrum disorder	University of California, San Francisco	Withdrawn	No outcome recorded
Phase 1	NCT01939639	Mar → Jun 2013	—	University Hospital, Bonn	Completed	No outcome recorded
Phase 1	NCT02052258	Jan 2013 → Dec 2015	opiate dependence	MacDonald, Kai, M.D.	Unknown	No outcome recorded
Phase 1	NCT01517360	Jan 2012 → Feb 2013	schizophrenia	VA Greater Los Angeles Healthcare System	Completed	No outcome recorded
Phase 1	NCT01607970	Aug 2011 → May 2012	—	University Hospital, Bonn	Completed	No outcome recorded
Phase 1	NCT01394471	Jul 2011 → Jan 2015	schizoaffective disorder, schizophrenia	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT01606462	Jun 2011 → Jun 2013	—	University Hospital, Bonn	Completed	No outcome recorded
Phase 1	NCT01386333	Jun 2011 → Oct 2013	frontotemporal dementia	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 1	NCT02302209	Apr 2011 → Oct 2017	autism spectrum disorder, schizophrenia	University of California, San Francisco	Completed	No outcome recorded
Phase 1	NCT01212185	Jul 2010 → Mar 2011	alcohol withdrawal	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1	NCT01093768	Feb 2010 → Apr 2013	autism spectrum disorder	National Institute of Mental Health (NIMH)	Completed	No outcome recorded
Phase 1	NCT00263796	Mar 2006 → Oct 2010	autism	Anagnostou, Evdokia, M.D.	Completed	No outcome recorded

Phase 1/29 trials
Phase 1/2	NCT05405257	May 2022 → Mar 2025	Ehlers-Danlos syndrome, hypermobility type	Baylor College of Medicine	Terminated	No outcome recorded Stop: Enrollment
Phase 1/2	NCT04306354	Sep 2018 → Jan 2020	cocaine abuse, substance withdrawal syndrome	Pontificia Universidade Católica do Rio Grande do Sul	Completed	No outcome recorded
Phase 1/2	NCT03119610	Sep 2017 → Dec 2018	muscular atrophy, obesity disorder	Sara Espinoza	Completed	No outcome recorded
Phase 1/2	NCT03272321	Jul 2017 → May 2018	—	KU Leuven	Completed	No outcome recorded
Phase 1/2	NCT03096249	Nov 2016 → May 2017	—	KU Leuven	Completed	No outcome recorded
Phase 1/2	NCT02548728	Feb → Dec 2016	opiate dependence, substance withdrawal syndrome	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 1/2	NCT01712646	Oct 2012 → Jun 2016	childhood-onset schizophrenia	National Institute of Mental Health (NIMH)	Terminated	No outcome recorded
Phase 1/2	NCT01856530	Jul 2012 → Aug 2013	social phobia	Stefan G. Hofmann	Completed	No outcome recorded
Phase 1/2	NCT01548521	Jul 2011 → Feb 2012	Prader-Willi syndrome	University Hospital, Toulouse	Completed	No outcome recorded
Phase 2110 trials · 2 met primary · 10 missed
Phase 2	NCT07430228	Oct 2026 → Dec 2027 expected	—	Wake Forest University Health Sciences	Enrolling by invitation	No outcome recorded
Phase 2	NCT06968481	May → Oct 2026 expected	—	Insud Pharma	Not yet recruiting	No outcome recorded
Phase 2	NCT07053774	Nov 2025 → Jun 2026	—	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 2	NCT07409753	Oct 2025 → Jun 2027 expected	—	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 2	NCT06808516	Jul 2025 → Dec 2026 expected	neurohypophyseal diabetes insipidus	University Hospital, Basel, Switzerland	Recruiting	No outcome recorded
Phase 2	NCT06945926	Jun 2025 → Jun 2026 overdue	avascular necrosis, lumbar spinal stenosis, rotator cuff syndrome, spinal cord injury	Zhejiang University	Not yet recruiting	No outcome recorded
Phase 2	NCT06676774	May 2025 → Feb 2027 expected	neurohypophyseal diabetes insipidus	University Hospital, Basel, Switzerland	Recruiting	No outcome recorded
Phase 2	NCT05488457	Jan 2025 → Dec 2026 expected	—	University of Chicago	Recruiting	No outcome recorded
Phase 2	NCT04433741	Jan → Dec 2025	chronic pain syndrome	Wake Forest University Health Sciences	Withdrawn	No outcome recorded
Phase 2	NCT04435704	Jan 2025 → Jan 2027	osteoarthritis, knee	Wake Forest University Health Sciences	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT06651476	Dec 2024 → Nov 2025	sunburn	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 2	NCT06194851	Oct 2024 → Sep 2028 expected	post-traumatic stress disorder	VA Office of Research and Development	Recruiting	No outcome recorded
Phase 2	NCT06550089	Oct 2024 → Oct 2026	pregnancy disorder	University of Chicago	Withdrawn	No outcome recorded
Phase 2	NCT05934812	Sep 2024 → Nov 2025	autism spectrum disorder	Oslo University Hospital	Unknown	No outcome recorded
Phase 2	NCT06881810	Aug 2024 → Mar 2028 expected	psychotic disorder	Central Institute of Mental Health, Mannheim	Recruiting	No outcome recorded
Phase 2	NCT06141447	May 2024 → Nov 2026 expected	hemorrhagic disease	University of Colorado, Denver	Recruiting	No outcome recorded
Phase 2	NCT07551882	Jan 2024 → Jun 2026 overdue	—	Sant Pau Research Institute	Recruiting	No outcome recorded
Phase 2	NCT04493229	Jan 2024 → Jan 2026	osteoarthritis, knee	Wake Forest University Health Sciences	Withdrawn	No outcome recorded
Phase 2	NCT04431193	Dec 2023 → Jan 2025	osteoarthritis, knee	Wake Forest University Health Sciences	Withdrawn	No outcome recorded
Phase 2	NCT03865615	Nov 2023 → Apr 2024	alcohol-related disorders	Jennifer Mitchell	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT06199076	Oct 2023 → Apr 2025	alcohol-related disorders	Karolinska Institutet	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT05929339	Aug 2023 → Oct 2024	chronic pain syndrome	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 2	NCT05754073	Aug 2023 → Aug 2027 expected	autism spectrum disorder, disease of bone structure	Elizabeth Austen Lawson	Recruiting	No outcome recorded
Phase 2	NCT05864508	Jul 2023 → Dec 2026 expected	autism spectrum disorder	University Hospital, Toulouse	Not yet recruiting	No outcome recorded
Phase 2	NCT05968651	Jun 2023 → Sep 2024	social phobia	University of Washington	Completed	No outcome recorded
Phase 2	NCT05326776	Apr → Aug 2023	—	University of California, San Diego	Completed	No outcome recorded
Phase 2	NCT05432089	Mar 2023 → Jul 2026	—	Shalvata Mental Health Center	Unknown	No outcome recorded
Phase 2	NCT05664516	Mar 2023 → Dec 2026 expected	binge eating disorder	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 2	NCT04429880	Jan 2023 → Jan 2024	osteoarthritis, knee	Wake Forest University Health Sciences	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT05679908	Dec 2022 → Oct 2023	migraine with aura, migraine without aura	Tonix Pharmaceuticals, Inc.	Completed	No outcome recorded
Phase 2	NCT04738838	May → Jul 2022	—	Florida Institute for Human and Machine Cognition	Completed	No outcome recorded
Phase 2	NCT05179421	May 2022 → Feb 2023	—	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 2	NCT06757517	Mar 2022 → Nov 2025	drug dependence	St. Olavs Hospital	Completed	No outcome recorded
Phase 2	NCT04732247	Feb 2022 → Sep 2023	—	Florida Institute for Human and Machine Cognition	Completed	No outcome recorded
Phase 2	NCT05207436	Jan → Sep 2022	post-traumatic stress disorder	San Diego Veterans Healthcare System	Completed	No outcome recorded
Phase 2	NCT05312008	Jan 2022 → Dec 2023	alcohol-related disorders	Indiana University	Terminated	No outcome recorded
Phase 2	NCT04427540	Dec 2021 → Jun 2022	osteoarthritis, knee	Wake Forest University Health Sciences	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2	NCT04551482	Jul 2021 → Dec 2026 expected	—	Massachusetts General Hospital	Recruiting	No outcome recorded
Phase 2	NCT04523922	Mar 2021 → Jun 2026 overdue	alcohol dependence, post-traumatic stress disorder	Medical University of South Carolina	Active not recruiting	No outcome recorded
Phase 2	NCT04724187	Feb → Aug 2021	—	Islamabad Medical and Dental College	Unknown	No outcome recorded
Phase 2	NCT04228289	Jan 2021 → Feb 2025	post-traumatic stress disorder	VA Office of Research and Development	Completed	No outcome recorded
Phase 2	NCT04427709	Nov 2020 → Dec 2026 expected	chronic pain syndrome, osteoarthritis, knee	Wake Forest University Health Sciences	Recruiting	No outcome recorded
Phase 2	NCT04431206	Nov 2020	osteoarthritis, knee	Wake Forest University Health Sciences	Terminated	No outcome recorded Stop: Business
Phase 2	NCT04386447	Sep → Oct 2020	COVID-19	Azienda Ospedaliero-Universitaria di Parma	Withdrawn	No outcome recorded
Phase 2	NCT03900754	Jan 2020 → Jan 2024	schizophrenia	VA Office of Research and Development	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT03846505	May 2019 → Jan 2024	alcohol-related disorders	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT03593473	Feb 2019 → Jul 2023	anxiety disorder, postpartum depression	University of North Carolina, Chapel Hill	Completed	Missed primary
Phase 2	NCT03370510	Dec 2018 → Jul 2021	autism spectrum disorder	Yale University	Terminated	No outcome recorded
Phase 2	NCT03497988	Sep 2018 → Jun 2020	obesity disorder	Shana McCormack, MD	Withdrawn	No outcome recorded Stop: Business
Phase 2	NCT03566069	Jun 2018 → Jun 2025	—	Shalvata Mental Health Center	Unknown	No outcome recorded
Phase 2	NCT03197662	Apr 2018 → Aug 2022	Prader-Willi syndrome, obesity, hyperphagia, and developmental delay	Eric Hollander	Completed	No outcome recorded
Phase 2	NCT03466671	Feb 2018 → Mar 2020	autism spectrum disorder	Hamamatsu University	Unknown	No outcome recorded
Phase 2	NCT03260920	Jan 2018 → Jun 2023	frontotemporal dementia	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Unknown	Met primary
Phase 2	NCT03016598	Jan 2018 → Feb 2020	substance abuse	VA Office of Research and Development	Completed	No outcome recorded
Phase 2	NCT03395730	Sep 2017 → Jan 2018	uterine disorder	Eslam Mohammed Abbas	Unknown	No outcome recorded
Phase 2	NCT03225456	Sep 2017 → Dec 2018	—	Yale-NUS College	Unknown	No outcome recorded
Phase 2	NCT03043053	Jul 2017 → May 2022	obesity disorder	Massachusetts General Hospital	Completed	Missed primary
Phase 2	NCT03046836	Jul 2017 → Apr 2021	alcohol-related disorders	Medical University of South Carolina	Completed	Missed primary
Phase 2	NCT03033784	May 2017 → Oct 2018	autism	Emory University	Completed	No outcome recorded
Phase 2	NCT02979093	May 2017 → May 2021	—	Lane Strathearn, MBBS PhD	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT02742532	Apr 2017 → Jul 2019	alcohol-related disorders, post-traumatic stress disorder	Jennifer Mitchell	Completed	No outcome recorded
Phase 2	NCT02824627	Jan 2017 → Aug 2021	disruptive behavior disorder, mood disorder	University of Nebraska	Completed	No outcome recorded
Phase 2	NCT03011307	Jan 2017 → Oct 2020	—	Wake Forest University Health Sciences	Terminated	Missed primary Stop: Enrollment
Phase 2	NCT02652195	Nov 2016 → Jun 2022	alcohol-related disorders	University of Utah	Unknown	No outcome recorded
Phase 2	NCT02849743	Oct 2016 → Apr 2021	acquired hypothalamic obesity, craniopharyngioma	Shana McCormack, MD	Completed	Missed primary
Phase 2	NCT03006380	Aug 2016 → Aug 2017	—	Ain Shams Maternity Hospital	Unknown	No outcome recorded
Phase 2	NCT02859571	Aug → Dec 2016	—	Zeynep Kamil Maternity and Pediatric Research and Training Hospital	Unknown	No outcome recorded
Phase 2	NCT03148899	Jul 2016 → Jun 2020	obstructive sleep apnea syndrome	George Washington University	Completed	No outcome recorded
Phase 2	NCT02918864	Jun 2016 → Sep 2021	autism spectrum disorder	Rush University Medical Center	Completed	Mixed
Phase 2	NCT04629885	May 2016 → May 2017	postmenopausal atrophic vaginitis	PepTonic Medical AB	Completed	No outcome recorded
Phase 2	NCT02710084	Apr 2016 → Jul 2020	Phelan-McDermid syndrome	Alexander Kolevzon	Completed	Missed primary
Phase 2	NCT03610633	Mar 2016 → Sep 2018	alcohol dependence	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT02629991	Oct 2015 → Dec 2016	Prader-Willi syndrome, obesity, hyperphagia, and developmental delay	Montefiore Medical Center	Completed	Mixed
Phase 2	NCT02546570	Aug 2015 → Aug 2016	post-traumatic stress disorder	Yale University	Completed	No outcome recorded
Phase 2	NCT02251912	Jul 2015 → Sep 2016	alcohol dependence	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 2	NCT02682784	Jul 2015 → Jul 2020	cocaine dependence	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT02847143	Apr 2015 → Apr 2018	—	Centre Hospitalier Universitaire de Besancon	Completed	No outcome recorded
Phase 2	NCT02405715	Feb 2015 → Aug 2016	depressive disorder	Concordia University, Montreal	Completed	No outcome recorded
Phase 2	NCT02127073	Jan 2015 → Jan 2017	ductal breast carcinoma in situ	Montefiore Medical Center	Terminated	No outcome recorded Stop: Business
Phase 2	NCT03238924	Jan 2015 → Dec 2016	post-traumatic stress disorder	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT02350946	Jan 2015 → Jan 2017	—	RWTH Aachen University	Unknown	No outcome recorded
Phase 2	NCT02671266	Dec 2014 → Oct 2017	body dysmorphic disorder, obsessive-compulsive disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT02497547	Oct 2014 → Jul 2015	—	PepTonic Medical AB	Completed	No outcome recorded
Phase 2	NCT02100956	Jun 2014 → Oct 2022	neuropathy, painful	Wake Forest University Health Sciences	Terminated	Met primary Stop: Enrollment
Phase 2	NCT02941692	Jun 2014 → Mar 2017	substance abuse	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT02493426	May 2014 → Mar 2021	autism spectrum disorder	University of Minnesota	Completed	No outcome recorded
Phase 2	NCT01914939	Apr 2014 → Nov 2017	autism spectrum disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 2	NCT01996605	Jan 2014 → Oct 2022	—	Wake Forest University Health Sciences	Terminated	No outcome recorded Stop: Enrollment
Phase 2	NCT01699997	Jan 2014 → Apr 2015	schizophrenia	IRCCS Centro San Giovanni di Dio Fatebenefratelli	Completed	Missed primary
Phase 2	NCT01937013	Sep 2013 → Dec 2017	frontotemporal dementia	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Completed	No outcome recorded
Phase 2	NCT01908205	Sep 2013 → Sep 2015	autism spectrum disorder	Holland Bloorview Kids Rehabilitation Hospital	Completed	No outcome recorded
Phase 2	NCT01839149	May 2013 → Oct 2015	—	Trigemina, Inc	Completed	No outcome recorded
Phase 2	NCT01963078	Apr 2013 → Jan 2015	post-traumatic stress disorder	Megan Moran-Santa Maria	Completed	No outcome recorded
Phase 2	NCT01568528	Mar 2013 → Mar 2017	schizophrenia	Emory University	Completed	No outcome recorded
Phase 2	NCT01722071	Oct 2012 → Sep 2013	—	Tiffany Love	Completed	No outcome recorded
Phase 2	NCT02079558	Sep 2012 → Sep 2013	—	Shahid Beheshti University of Medical Sciences	Completed	No outcome recorded
Phase 2	NCT01598623	May 2012 → Feb 2014	—	Sheba Medical Center	Unknown	Missed primary
Phase 2	NCT01987804	Jan → Dec 2012	postmenopausal atrophic vaginitis	PepTonic Medical AB	Completed	No outcome recorded
Phase 2	NCT01963091	Jul 2011 → Oct 2012	cocaine dependence	Medical University of South Carolina	Completed	No outcome recorded
Phase 2	NCT01256060	Nov 2010 → Mar 2013	autism spectrum disorder	Evdokia Anagnostou	Completed	No outcome recorded
Phase 2	NCT01432470	Aug 2010 → Jun 2011	postmenopausal atrophic vaginitis	PepTonic Medical AB	Completed	No outcome recorded
Phase 2	NCT01183221	Jun 2010 → Apr 2014	autism, autism spectrum disorder 1	Alexander Kolevzon	Completed	No outcome recorded
Phase 2	NCT00884897	Jan 2010 → Jan 2012	CGF1, social phobia	University of Maryland, Baltimore	Completed	No outcome recorded
Phase 2	NCT00663039	Oct 2009 → Jul 2015	schizophrenia	University of Maryland, Baltimore	Completed	Missed primary
Phase 2	NCT01038570	Jun → Sep 2009	Prader-Willi syndrome	University Hospital, Toulouse	Completed	No outcome recorded
Phase 2	NCT00813436	May 2008 → Jan 2010	schizophrenia	Shalvata Mental Health Center	Unknown	No outcome recorded
Phase 2	NCT01254045	Feb 2007 → Nov 2009	fragile X syndrome	Stanford University	Completed	No outcome recorded
Phase 2	NCT03228901	Jan 2007 → Jul 2009	—	Yale-NUS College	Completed	No outcome recorded
Phase 2	NCT00490802	Jun 2006 → Sep 2011	autism	Evdokia Anagnostou	Completed	Missed primary
Phase 2	NCT00393731	Jan 2004 → Aug 2007	—	The University of Texas Health Science Center, Houston	Completed	No outcome recorded

Phase 2/310 trials
Phase 2/3	NCT06248710	Jan → Dec 2024 overdue	depressive disorder, zoophilia	Dr. Karin Hediger	Recruiting	No outcome recorded
Phase 2/3	NCT05627791	Nov 2022 → Jul 2023	postmenopausal atrophic vaginitis	Department of Medical Services Ministry of Public Health of Thailand	Terminated	No outcome recorded
Phase 2/3	NCT05298085	Apr 2022 → Apr 2023	Prader-Willi syndrome	University Hospital, Toulouse	Completed	No outcome recorded
Phase 2/3	NCT04903002	Apr 2022 → Mar 2026 overdue	chronic pain syndrome	Memorial University of Newfoundland	Active not recruiting	No outcome recorded
Phase 2/3	NCT05093296	Dec 2021 → Jul 2023	alcohol dependence	Central Institute of Mental Health, Mannheim	Completed	No outcome recorded
Phase 2/3	NCT02409862	Jan → Aug 2019	—	University of Florida	Withdrawn	No outcome recorded Stop: Enrollment
Phase 2/3	NCT03819231	Oct 2018 → Dec 2023	—	University of Southern California	Terminated	No outcome recorded
Phase 2/3	NCT03001635	Jan 2017 → Dec 2018	myocardial infarction	Sheba Medical Center	Unknown	No outcome recorded
Phase 2/3	NCT02888574	Nov 2016 → Dec 2018	chronic pain syndrome, pelvis syndrome	University of Calgary	Completed	No outcome recorded
Phase 2/3	NCT02508103	Jul 2015 → Jun 2016	premenstrual dysphoric disorder	University of North Carolina, Chapel Hill	Completed	No outcome recorded
Phase 318 trials · 1 met primary · 2 missed
Phase 3	NCT06010368	Oct 2024 → Dec 2025 overdue	—	Cairo University	Not yet recruiting	No outcome recorded
Phase 3	NCT06725004	Jan → Dec 2023	female infertility, polycystic ovary syndrome	Shakeela Ishrat	Completed	No outcome recorded
Phase 3	NCT04949633	Sep 2021 → Sep 2026 overdue	cervix disorder	University Hospital, Tours	Recruiting	No outcome recorded
Phase 3	NCT04210310	Jan 2020 → May 2022	tinnitus	NYU Langone Health	Terminated	No outcome recorded
Phase 3	NCT03640156	Jul 2018 → Dec 2019	autism spectrum disorder	KU Leuven	Completed	No outcome recorded
Phase 3	NCT03339024	Nov 2017 → Mar 2019	alcohol dependence	Norwegian University of Science and Technology	Completed	No outcome recorded
Phase 3	NCT02985749	Oct 2017 → Jan 2019	autism spectrum disorder 1	Massachusetts General Hospital	Completed	No outcome recorded
Phase 3	NCT02903251	Oct 2016 → Jan 2018	alcohol dependence	Norwegian University of Science and Technology	Completed	Missed primary
Phase 3	NCT02794779	Jul 2016 → Dec 2017	—	Brasilia University Hospital	Unknown	No outcome recorded
Phase 3	NCT02618499	May → Nov 2016	—	Fundacion para la Salud Materno Infantil	Terminated	Missed primary
Phase 3	NCT02720978	May 2016 → May 2019	—	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 3	NCT02684305	Apr 2016 → Apr 2018	—	Tel-Aviv Sourasky Medical Center	Unknown	No outcome recorded
Phase 3	NCT02319707	Sep 2015 → Jan 2017	—	Yariv yogev	Unknown	No outcome recorded
Phase 3	NCT01932060	Aug 2013 → Sep 2015	—	Stanford University	Completed	No outcome recorded
Phase 3	NCT01710566	Jul 2013 → Dec 2014	—	Gynuity Health Projects	Withdrawn	No outcome recorded
Phase 3	NCT01767025	Nov → Dec 2012	—	University Ghent	Completed	No outcome recorded
Phase 3	NCT01397630	Apr 2012 → Oct 2013	dystocia	Ottawa Hospital Research Institute	Terminated	No outcome recorded Stop: Enrollment
Phase 3	NCT01094028	Dec 2009 → Mar 2010	—	Erzincan Military Hospital	Completed	Met primary

Phase 438 trials · 1 met primary · 7 missed
Phase 4	NCT07636421	Aug 2026 → Apr 2028 expected	uterine disorder	Mansoura University	Recruiting	No outcome recorded
Phase 4	NCT07566455	Aug 2025 → Feb 2026	—	CMH Multan Institute of Medical Sciences	Completed	No outcome recorded
Phase 4	NCT06990217	Jun 2025 → Jun 2027 expected	—	HaEmek Medical Center, Israel	Not yet recruiting	No outcome recorded
Phase 4	NCT05823441	Jun 2023 → Jan 2024	—	Peking University People's Hospital	Completed	No outcome recorded
Phase 4	NCT05608070	Jun 2023 → Jun 2024	—	Beth Israel Deaconess Medical Center	Withdrawn	No outcome recorded Stop: Business
Phase 4	NCT05568745	Jan 2023 → Feb 2025	cervix disorder, preterm premature rupture of the membranes	University Hospital, Clermont-Ferrand	Unknown	No outcome recorded
Phase 4	NCT05289869	Apr → Sep 2022	—	Ohio State University	Completed	No outcome recorded
Phase 4	NCT04760496	Oct 2021 → Dec 2024	obesity disorder	Assistance Publique - Hôpitaux de Paris	Completed	No outcome recorded
Phase 4	NCT03991091	Jan 2020 → Apr 2022	—	Assistance Publique - Hôpitaux de Paris	Completed	Missed primary
Phase 4	NCT03749902	Jan 2020 → Jul 2022	—	University of Liverpool	Completed	No outcome recorded
Phase 4	NCT04105998	Oct 2019 → Nov 2021	chronic pain syndrome	Wake Forest University Health Sciences	Completed	Missed primary
Phase 4	NCT03935399	Aug 2019 → Mar 2020	chronic pain syndrome	Wake Forest University Health Sciences	Completed	Missed primary
Phase 4	NCT03929367	May 2019 → Mar 2020	chronic pain syndrome	Wake Forest University Health Sciences	Completed	No outcome recorded
Phase 4	NCT03361124	Mar 2019 → Mar 2020	anemia, uterine disorder	Milton S. Hershey Medical Center	Withdrawn	No outcome recorded
Phase 4	NCT03232918	Feb 2019 → Dec 2025 overdue	cardiac rhythm disease	Unyime Ituk	Recruiting	No outcome recorded
Phase 4	NCT03937401	Feb → Dec 2019	adenomyosis, leiomyoma	Turku University Hospital	Unknown	No outcome recorded
Phase 4	NCT03604874	Sep 2018 → Aug 2020	dystocia	Assiut University	Completed	No outcome recorded
Phase 4	NCT03245437	Jan 2018 → Jul 2024	schizophrenia	University of California, Los Angeles	Completed	No outcome recorded
Phase 4	NCT03308643	Oct 2017 → May 2018	uterine corpus leiomyoma	Kanuni Sultan Suleyman Training and Research Hospital	Completed	Met primary
Phase 4	NCT03140488	Jun 2017 → Oct 2018	obesity disorder	University of Arizona	Completed	Missed primary
Phase 4	NCT02969447	Oct 2016 → Aug 2017	placenta disorder	University Hospital, Bordeaux	Completed	No outcome recorded
Phase 4	NCT03344302	Oct 2016 → Aug 2017	—	Assiut University	Completed	No outcome recorded
Phase 4	NCT02801227	Sep 2016 → Sep 2017	preterm premature rupture of the membranes	Shaare Zedek Medical Center	Unknown	No outcome recorded
Phase 4	NCT02595749	Jul 2016 → Jul 2019	nicotine dependence	University of Southern California	Completed	No outcome recorded
Phase 4	NCT02737254	Mar → Oct 2016	—	Universitaire Ziekenhuizen KU Leuven	Completed	No outcome recorded
Phase 4	NCT03010670	Jan → Aug 2016	—	KU Leuven	Completed	No outcome recorded
Phase 4	NCT02487797	Sep 2015 → Sep 2020	dystocia	Northwestern University	Completed	Missed primary
Phase 4	NCT02940574	Apr 2015 → Dec 2016	autism spectrum disorder	KU Leuven	Completed	Missed primary
Phase 4	NCT02336568	Mar 2015 → Dec 2016	post-traumatic stress disorder	Rambam Health Care Campus	Unknown	No outcome recorded
Phase 4	NCT01829516	May 2013 → May 2014	substance-related disorder	University of California, San Francisco	Completed	No outcome recorded
Phase 4	NCT01827124	Apr → Nov 2013	—	Wafaa Uthman Ahmed	Unknown	No outcome recorded
Phase 4	NCT01325168	Aug 2011 → Aug 2012	post-traumatic stress disorder	Rambam Health Care Campus	Completed	No outcome recorded
Phase 4	NCT01252342	Aug 2011 → Apr 2012	uterine disorder	University of Saskatchewan	Withdrawn	No outcome recorded
Phase 4	NCT01236482	Nov 2010 → May 2011	—	Hadassah Medical Organization	Unknown	No outcome recorded
Phase 4	NCT01631682	Nov 2010 → Jan 2015	post-traumatic stress disorder	Massachusetts General Hospital	Completed	No outcome recorded
Phase 4	NCT01081249	Dec 2008 → Jul 2012	anxiety	MacDonald, Kai, M.D.	Completed	No outcome recorded
Phase 4	NCT00790062	Nov 2008 → Jun 2010	uterine disorder	University of Alabama at Birmingham	Completed	Missed primary
Phase 4	NCT00785395	Jun → Aug 2008	uterine disorder	IWK Health Centre	Completed	No outcome recorded

Phase not applicable139 trials · 3 met primary · 10 missed
—	NCT07838493	Sep → Dec 2026 expected	—	University of Electronic Science and Technology of China	Recruiting	No outcome recorded
—	NCT07815496	Sep → Dec 2026 expected	—	University of Electronic Science and Technology of China	Recruiting	No outcome recorded
—	NCT07687355	Jul → Oct 2026 expected	—	Hayatabad Medical Complex	Not yet recruiting	No outcome recorded
—	NCT07559656	Apr → Sep 2026 overdue	—	University of Electronic Science and Technology of China	Recruiting	No outcome recorded
—	NCT07366359	Feb 2026 → Dec 2027 expected	cervix disorder, preterm premature rupture of the membranes	National Hospital of Obstetrics and Gynecology	Recruiting	No outcome recorded
—	NCT07425938	Jan → Apr 2026 overdue	—	University of Electronic Science and Technology of China	Recruiting	No outcome recorded
—	NCT07318467	Jan → Jun 2026 overdue	—	Cairo University	Not yet recruiting	No outcome recorded
—	NCT07162584	Sep 2025 → Jan 2026 overdue	—	University of Electronic Science and Technology of China	Recruiting	No outcome recorded
—	NCT07006896	Jul 2025 → Jul 2026 overdue	—	University of Pennsylvania	Active not recruiting	No outcome recorded
—	NCT06881459	Mar → Jul 2025	type 1 diabetes mellitus	University Hospital, Gentofte, Copenhagen	Completed	No outcome recorded
Show all 139 trials opens the full record — a long page
Comparator or background therapy225 trials
Phase 0	NCT05761860 Comparator	Sep 2023 → Dec 2026 expected	—	University of Florida	Recruiting	No outcome recorded
Phase 0	NCT04218409 Comparator	Sep 2021 → Dec 2026 expected	—	University of Florida	Recruiting	No outcome recorded
Phase 0	NCT04478942 Comparator	Oct 2020 → Jan 2025	preterm premature rupture of the membranes	University of Wisconsin, Madison	Completed	No outcome recorded
Phase 0	NCT04549012 Comparator	Sep 2020 → Sep 2021	—	Ain Shams University	Unknown	No outcome recorded
Phase 0	NCT04089176 Comparator	Feb → Apr 2019	—	Department of Medical Services Ministry of Public Health of Thailand	Completed	No outcome recorded
Show all 225 trials opens the full record — a long page

News releases announcing trial results or a regulatory action · 11

Date	Issuer	Release
2024-03-25	Tonix Pharmaceuticals, Inc.	Regulatory Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome tonixpharma.com ↗ Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to TNX-2900* (intranasal potentiated oxytocin), a proprietary magnesium (Mg2 + )-potentiated formulation of intranasal oxytocin, to treat Prader-Willi syndrome (PWS) in children and adolescents.
2023-12-04	Tonix Pharmaceuticals, Inc.	Regulatory Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity tonixpharma.com ↗
2023-09-18	Tonix Pharmaceuticals, Inc.	Results Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress tonixpharma.com ↗ The presentations show that oxytocin receptors are co-expressed with calcitonin gene-related peptide (CGRP) on human trigeminal ganglia neurons, which is similar to Professor Yeomans’ previous findings in animal trigeminal ganglia.
2023-01-31	Tonix Pharmaceuticals, Inc.	Results Tonix Pharmaceuticals Announces Presentation of Clinical and Non-Clinical TNX-1900 Data at the Annual Headache Cooperative of the Pacific (HCOP) Winter Conference tonixpharma.com ↗ A signal was observed in the trigeminal ganglia, indicating that intranasal oxytocin plus Mg ++ delivers oxytocin to the trigeminal ganglia which have known roles in migraine headache.
2022-11-16	Tonix Pharmaceuticals, Inc.	Results Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience tonixpharma.com ↗
2022-06-21	Tonix Pharmaceuticals, Inc.	Results Tonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin Analgesia tonixpharma.com ↗ The paper includes data showing the enhancing effects of magnesium (Mg 2 + ) on the activity of intranasal oxytocin in an animal model of craniofacial pain.
2021-11-23	Tonix Pharmaceuticals, Inc.	Regulatory Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs tonixpharma.com ↗ “We are excited to have received the FDA’s IND clearance to begin clinical trials for TNX-1900 in prevention of migraine headaches in chronic migraineurs,” said Seth Lederman, M.D., President and CEO of Tonix.
2020-08-04	Tonix Pharmaceuticals, Inc.	Results Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference tonixpharma.com ↗ The data show that intranasal oxytocin, but not intravenous oxytocin or vehicle, attenuated both reactive and spontaneous pain following mild traumatic brain injury in an animal model.
2020-07-27	Tonix Pharmaceuticals, Inc.	Results Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference tonixpharma.com ↗ Intranasal (IN) Oxytocin Relieves Pain and Depressive Behavior in a Rodent Model of Mild Traumatic Brain Injury (TBI)
2017-04-12	PepTonic Medical AB	Results Informationsmöte den 11/4 peptonicmedical.se ↗ Vi fortsätter att analysera data från fas 2b-studien för att se hur det kommer sig att inte oxotycin har gett det förväntade resultaten.
2017-03-15	PepTonic Medical AB	Results Peptonic Medical announces results of the first part of its phase 2b study peptonicmedical.se ↗ However, further analyses of the study data show that the gel, both without and with the active ingredient (oxytocin), had a marked and statistically significant alleviating effect on the Most Bothersome Symptoms (MBS) after the twelve week treatment.

All press releases naming this drug 28 releases

Date	Issuer	Release
2026-03-26	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain tonixpharma.com ↗
2025-10-22	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces First Patient Dosed in the Investigator-Initiated FOCUS Study of Tonix’s Intranasal Potentiated Oxytocin in AVP-D Conducted by Massachusetts General Hospital tonixpharma.com ↗
2025-09-29	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Plans to Initiate Prader-Willi Syndrome Phase 2 Trial of TNX-2900 (Intranasal Potentiated Oxytocin) in 2026 tonixpharma.com ↗
2024-03-25	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome tonixpharma.com ↗
2024-03-21	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting tonixpharma.com ↗
2023-12-04	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces IND Clearance by the FDA for Phase 2 Trial of TNX-2900 for the Treatment of Prader-Willi Syndrome, the Most Common Genetic Cause of Life-Threatening Childhood Obesity tonixpharma.com ↗
2023-11-13	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Enrollment Initiated in Mass General Brigham Phase 2 Investigator-Initiated Study of TNX-1900 (Intranasal Potentiated Oxytocin) for Bone Health in Children with Autism Spectrum Disorder tonixpharma.com ↗
2023-10-26	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Completes Clinical Stage of Phase 2 PREVENTION Study of TNX-1900 for the Prevention of Migraine Headaches in Chronic Migraineurs tonixpharma.com ↗
2023-10-04	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Issuance of EU Patent Covering Intranasal Potentiated Oxytocin (TNX-1900) for the Treatment of Pain tonixpharma.com ↗
2023-09-18	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Presentation of Non-Clinical Studies Supporting the Mechanism of TNX-1900 (Intranasal Potentiated Oxytocin) at the 2023 International Headache Congress tonixpharma.com ↗
2023-07-31	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Enrollment Initiated in the MGH Phase 2 ‘STROBE’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Binge-Eating Disorder tonixpharma.com ↗
2023-07-17	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Agreement and Initiation of Enrollment in Phase 2 Trial with the University of Washington to Study TNX-1900 (Potentiated Intranasal Oxytocin) for Social Anxiety Disorder tonixpharma.com ↗
2023-07-10	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Initiation of Enrollment in the MGH Phase 2 ‘POWER’ Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the Treatment of Pediatric Obesity tonixpharma.com ↗
2023-05-22	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Clinical Proof-of-Concept Study of TNX-1900 (Intranasal Potentiated Oxytocin) tonixpharma.com ↗
2023-02-06	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Initiates Enrollment in Phase 2 ‘PREVENTION’ Study of Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headaches in Chronic Migraineurs tonixpharma.com ↗
2023-01-31	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Presentation of Clinical and Non-Clinical TNX-1900 Data at the Annual Headache Cooperative of the Pacific (HCOP) Winter Conference tonixpharma.com ↗
2022-11-16	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Data from an in vitro Study of the Impact of Oxytocin on Human Neurons at Neuroscience 2022, the Annual Meeting of the Society for Neuroscience tonixpharma.com ↗
2022-08-01	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Issuance of U.S. Patent Covering Potentiated Intranasal Oxytocin (TNX-1900) for the Treatment of Pain tonixpharma.com ↗
2022-06-21	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Publication of Paper in Pharmaceutics on the Enhancing Effect That Magnesium Contributes to in vivo Intranasal Oxytocin Analgesia tonixpharma.com ↗
2022-03-07	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Collaboration with Massachusetts General Hospital to Evaluate TNX-1900 (Intranasal Potentiated Oxytocin) for Treating Binge Eating Disorder tonixpharma.com ↗
2022-02-28	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces Research Agreement with the French National Institute of Health and Medical Research (Inserm) to Study the Mechanism of Oxytocin-Mediated Improvement of Eating Behaviors in Prader-Willi Mice tonixpharma.com ↗
2021-11-23	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces FDA Clearance of the IND for Potentiated Intranasal Oxytocin (TNX-1900) for the Prevention of Migraine Headache in Chronic Migraineurs tonixpharma.com ↗
2020-12-22	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin) tonixpharma.com ↗
2020-08-04	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 are Posted at the AAN Sports Concussion Virtual Conference tonixpharma.com ↗
2020-07-27	Tonix Pharmaceuticals, Inc.	Tonix Pharmaceuticals Announces that Results from a Preclinical Study of TNX-1900 Will be Presented in a Poster at the AAN Sports Concussion Virtual Conference tonixpharma.com ↗
2017-04-12	PepTonic Medical AB	Informationsmöte den 11/4 peptonicmedical.se ↗
2017-03-15	PepTonic Medical AB	Peptonic Medical announces results of the first part of its phase 2b study peptonicmedical.se ↗
2014-09-25	GlaxoSmithKline	International collaboration to develop inhaled form of oxytocin to manage bleeding after childbirth in developing countries gsk.com ↗

Evidence & citations 29 cited values

Every value below carries the sentence it was read from. 628 sources stand behind the page.

Field	Value	Cited text
Known as	Oxytocin	“This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure...” NCT03860233 ↗ 599 “The role of oxytocin (OT) is already known in the regulation of satiety but some clinical studies demonstrated that OT participates also in the regulation of social behavior by...” NCT01038570 ↗ “This study will be carried out at Bangabandhu Sheikh Mujib Medical University (BSMMU) within six months after approval. This is a Randomized Control Trial which will compare...” NCT02396303 ↗ “one ampoule of syntometrine (Novartis, Basel, Switzerland), which consisted of 5 IU of oxytocin and 500 microgram of ergometrine diluted in 10 ml of Ringer's lactate solution...” NCT03693599 ↗ “In Oxytocin group (n=111), patients will receive 10 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) given as infusion in 500 ml lactated ringer/s solution at a rate of...” NCT06060327 ↗ “Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24...” NCT02872467 ↗ “Intravenous administration of Actovegin, vitamins B1, B6, B12, C, oxytocin/dexamethasone, calcium gluconate, etc in 250 ml normal saline administered during approximately 2 hours” NCT03543917 ↗ “Intravenous oxytocin titration has a prime position as a choice agent for induction of labour following term PROM as it has been shown to be efficacious for such purpose.” NCT06343480 ↗ “Intravenous combination of 5 IU oxytocin and 0.2 mg ergometrine (300 women) after fetal extraction and before placental removal.” NCT02044549 ↗ “intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse” NCT02229721 ↗ “nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)” NCT01325168 ↗ Show 589 more sources
Known as	d5OT	“A single, 1 International Unit (IU) bolus of deuterated oxytocin (d5OT) will be given to the subject” NCT05488457 ↗
Known as	deuterated oxytocin	“A single, 1 International Unit (IU) bolus of deuterated oxytocin (d5OT) will be given to the subject” NCT05488457 ↗
Known as	GR121619	“A Single Centre, Single Blind Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Doses of Oxytocin (GR121619) Administered Via an Inhaled Route in...” NCT02542813 ↗
Known as	IN-OXT	“intranasal oxytocin (IN-OXT) vs. placebo” NCT02629991 ↗ 3 “Intranasal Oxytocin (IN-OXT)” NCT04789148 ↗ “Intranasal Oxytocin (IN-OXT)” NCT07551882 ↗ “Intranasal Oxytocin (IN-OXT)” NCT06605300 ↗
Known as	Inj. Linda	“The participants in experimental group will receive inj. (injection) oxytocin 10 IU (Inj. Linda 10 unit, Nuvista Pharmaceuticals Limited) intramuscular as trigger” NCT06725004 ↗
Known as	Ocytocin	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04046510 ↗
Known as	OCYTOCINA	ClinicalTrials.gov intervention name — accepted as the source's own label NCT02007447 ↗
Known as	OXT	“The treatment is aimed at enhancing maternal bonding, reducing postpartum depression (PPD) and anxiety in mothers at risk, and promoting child development. To this end, the...” NCT02505984 ↗ 21 “The present study examines the impact of oxytocin (OXT) and Pivotal Response Treatment (PRT) on the development of language, social, and play skills in young children with...” NCT03370510 ↗ “Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment,...” NCT03891095 ↗ “Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment,...” NCT03597893 ↗ “Oxytocin (OXT), a neuropeptide produced in the hypothalamus, is a key modulator of complex socioaffective responses including affiliation, social approach and attachment,...” NCT03428906 ↗ “Oxytocin (OXT), a neuropeptide closely associated with AVP in terms of anatomical location and function, is known to play a critical role in social, emotional, and behavioral...” NCT06808516 ↗ “Endogenous oxytocin (OXT) has been a focus of prior psychiatric research due to its role in pro-social behavior, and modulation of response to social/emotional stimuli.” NCT03863288 ↗ “Emerging evidence suggests that the neuropeptide oxytocin (OXT) may be a blood-based biomarker of social functioning and a possible treatment for ASD.” PMID 28696286 ↗ Jul 2017 “The neuropeptide oxytocin (OXT) may facilitate social interactions either by increasing their rewarding experience or by attenuating anxiety” PMID 30086408 ↗ Aug 2018 “Oxytocin (OXT), a neuropeptide involved in social cognition, is a potential therapeutic agent for alleviating social dysfunction.” PMID 33587397 ↗ Mar 2021 “The hypothalamic peptide oxytocin (OXT) has anxiolytic effects both in healthy participants and patients with anxiety disorders” NCT03829839 ↗ Show 11 more sources
Known as	OXY	“One potential compound is oxytocin (OXY), which proved beneficial effects on alcohol craving and stress reactivity in preliminary clinical studies and synergism with NTX effects.” PMID 35410938 ↗ Apr 2022
Known as	OXYTIP	“Oxytocin (OXYTIP; manufactured by IPDIC, Rasht, Iran), 5 IU and hCG (Choriomon; manufactured by IBSA Institute Biochimique SA, CH-6903 Lugano), 5000 IU were also administrated...” NCT00844350 ↗
Known as	Oxytocin (Syntocinon)	“Oxytocin (Syntocinon)” NCT02205034 ↗
Known as	Oxytocin Grindeks	“Oxytocin Grindeks 10 IU/ml- solution for injection” NCT06990217 ↗
Known as	Oxytocin: Syntocinon Nasal Spray	“Oxytocin: Syntocinon Nasal Spray” NCT01566539 ↗
Known as	Oxytocin: Syntocinon-Spray, Novartis	“Oxytocin: Syntocinon-Spray, Novartis” NCT01606462 ↗ 2 “Oxytocin: Syntocinon-Spray, Novartis” NCT01607970 ↗ “Oxytocin: Syntocinon-Spray, Novartis” NCT01701180 ↗
Known as	Pitocin	“they then received a single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) during the second experimental session, which...” NCT02595749 ↗ 14 “A single 40 IU dose of Pitocin (oxytocin, USP; concentration = 10 IU/1 mL; PAR Pharmaceuticals, NY, USA) will be self-administered to each participant.” NCT03819231 ↗ “Prior literature has examined the use of Pitocin (Oxytocin), vaginal and oral misoprostol, and dinoprost with mixed results.” NCT04028765 ↗ “The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl” NCT02684305 ↗ “up titration of Pitocin if contractions are inadequate” NCT06702670 ↗ “10 IU oxytocin (Pitocin) for intramuscular injection” NCT03935399 ↗ “Intramuscular injection of Oxytocin (Pitocin®)” NCT04427709 ↗ “Oxytocin (also: syntocinon, pitocin)” NCT00813436 ↗ “oxytocin (Pitocin)” NCT00914953 ↗ NCT01615107 ↗ NCT06259097 ↗ Show 4 more sources
Known as	RVG 03716	“Syntocinon nasal spray (40 IU/ml; oxytocin, product code RVG 03716)” NCT04443647 ↗
Known as	Synpitan forte	“Group II: Oxytocin(Synpitan forte®; Deva Pharma, Istanbul, Turkey)” NCT05467462 ↗ 1 “Group I: Oxytocin(Synpitan forte®; Deva Pharma, Istanbul, Turkey)” NCT05083910 ↗
Known as	synthetic oxytocin	“Syntocinon (synthetic oxytocin)” NCT02090829 ↗
Known as	Syntocinon	“An equal volume of normal saline syringe in a double blinded manner will be intravenously administered to the OXYtocin group 30 min before surgery and will be followed by one...” NCT03892668 ↗ 45 “Patients will self-administer a 2-week course of 24-IU intranasal oxytocin \[4-IU per puff (12-IU delivered to each nostril); Syntocinon, Novartis, Switzerland\], twice per day...” NCT04903002 ↗ “Syntocinon spray, 24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24...” NCT02872467 ↗ “In Oxytocin group (n=111), patients will receive 10 IU oxytocin (Syntocinon, Novartis, Basel, Switzerland) given as infusion in 500 ml lactated ringer/s solution at a rate of...” NCT06060327 ↗ “Other names are Pitocin, syntocinon given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been...” NCT01719952 ↗ “OBJECTIVE: To determine the safety and tolerability of 3 doses of intranasal oxytocin (Syntocinon; Novartis, Bern, Switzerland) administered to patients with frontotemporal...” PMID 25503617 ↗ Dec 2014 “10 IU of oxytocin (Syntocinon, Novartis, Basel, Switzerland) were diluted in 500 mL of normal saline and administered through intravenous infusion over 30 minutes.” NCT06889155 ↗ “Patients will receive 5 units of oxytocin ( Syntocinon ®) as a 250 ml 0.9% NaCl infusion at admission to high dependency obstetric unit after cesarean section.” NCT04201665 ↗ “Participants will self-administer a single dose of 24 IU oxytocin (Syntocinon, Novartis; three puffs per nostril, each with 4 IU oxytocin, 6 puffs total).” NCT02443727 ↗ “Group 1 will receive Carbetocin 100 µgm (Pabal® Ferring, UK) and group 2 will receive oxytocin 5IU (Syntocinon®, Novartis, Switzerland).” NCT02303418 ↗ “participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).” NCT02393443 ↗ Show 35 more sources
Known as	Syntocinon Nasal Spray	“A single dose of 80 I.U. oxytocin in aerosol form (Syntocinon® nasal spray) is administered via 20 puffs 2 times per week intranasally.” NCT06881810 ↗ 3 “Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)” NCT03136263 ↗ “Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks” NCT01308749 ↗ “Oxytocin intranasal spray is manufactured as the Syntocinon Nasal Spray.” NCT01834261 ↗
Known as	Syntocinon-Spray	“Subjects receiving an intranasal spray of OXT (24 IU or 40.32 mg; Syntocinon-spray; Novartis, Switzerland)” NCT03891095 ↗ 1 “Oxytocin: Syntocinon-Spray, Novartis” NCT02156661 ↗
Known as	TI-001	“TI-001 is intranasal oxytocin” NCT01839149 ↗
Known as	TNX-1900	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05679908 ↗
Known as	TTA-121	ClinicalTrials.gov intervention name — accepted as the source's own label NCT03466671 ↗
Action	Inhibit	“Oxytocin administered peripherally inhibits dopamine transmission” NCT00506909 ↗
Modality	Peptide	“Oxytocin is a neurohypophyseal peptide” NCT00506909 ↗
Route	Intravenous	“40 IU Oxytocin IV” NCT00116350 ↗
Target	OXTR	“Oxytocin acts directly on the myometrium through the oxytocin receptor(OXTR) and stimulates contractions.” NCT04595812 ↗